Cubist Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CUBIST, and when can generic versions of CUBIST drugs launch?
CUBIST has seven approved drugs.
There are thirty US patents protecting CUBIST drugs.
There are three hundred and forty-two patent family members on CUBIST drugs in fifty-three countries and fifty-five supplementary protection certificates in eighteen countries.
Summary for Cubist
International Patents: | 342 |
US Patents: | 30 |
Tradenames: | 6 |
Ingredients: | 5 |
NDAs: | 7 |
PTAB Cases with Cubist as patent owner: | See PTAB cases with Cubist as patent owner |
Drugs and US Patents for Cubist
Expired US Patents for Cubist
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-002 | Sep 12, 2003 | 5,912,226 | ⤷ Try a Trial |
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-001 | Sep 12, 2003 | 8,058,238 | ⤷ Try a Trial |
Cubist Pharms | ENTEREG | alvimopan | CAPSULE;ORAL | 021775-001 | May 20, 2008 | 6,469,030 | ⤷ Try a Trial |
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-001 | Sep 12, 2003 | 5,912,226 | ⤷ Try a Trial |
Cubist Pharms | ENTEREG | alvimopan | CAPSULE;ORAL | 021775-001 | May 20, 2008 | 5,250,542 | ⤷ Try a Trial |
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-001 | Sep 12, 2003 | RE39071 | ⤷ Try a Trial |
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-001 | Sep 12, 2003 | 6,852,689 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for CUBIST drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Capsules | 12 mg | ➤ Subscribe | 2017-06-16 |
➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2008-11-19 |
➤ Subscribe | Tablets | 200 mg | ➤ Subscribe | 2015-05-27 |
International Patents for Cubist Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 2904808 | ⤷ Try a Trial |
China | 102614207 | ⤷ Try a Trial |
Lithuania | 2125850 | ⤷ Try a Trial |
Australia | 2003274754 | ⤷ Try a Trial |
Cyprus | 1117501 | ⤷ Try a Trial |
South Korea | 102181474 | ⤷ Try a Trial |
Peru | 20120585 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cubist Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1539977 | SPC/GB15/020 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: FIDAXOMICIN; REGISTERED: UK EU/1/11/733/001 20111207; UK EU/1/11/733/002 20111207; UK EU/1/11/733/003 20111207; UK EU/1/11/733/004 20111207 |
1556389 | 122015000113 | Germany | ⤷ Try a Trial | PRODUCT NAME: CEFTOLOZAN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON, INSBESONDERE EIN SCHWEFELSAEURESALZ; REGISTRATION NO/DATE: EU/1/15/1032/001 20150918 |
1556389 | 602 | Finland | ⤷ Try a Trial | |
1556389 | C01556389/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: CEFTOLOZAN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65472 03.03.2016 |
1699784 | C 2015 035 | Romania | ⤷ Try a Trial | PRODUCT NAME: TEDIZOLIDOPTIONAL SUB FORMA DE ESTER, IN PARTICULAR FOSFATUL SAU O SARE ACCEPTABILA FARMACEUTIC AACESTUIA; NATIONAL AUTHORISATION NUMBER: EU/1/15/991; DATE OF NATIONAL AUTHORISATION: 20150323; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/991; DATE OF FIRST AUTHORISATION IN EEA: 20150323 |
1699784 | C20150036 00229 | Estonia | ⤷ Try a Trial | PRODUCT NAME: TEDISOLIIDFOSFAAT;REG NO/DATE: EU/1/15/991 25.03.2015 |
1539977 | C300727 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: FIDAXOMICINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/733/001-004 20111205 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.